Results 121 to 130 of about 1,844 (152)
Some of the next articles are maybe not open access.
Advances in Anesthesia
Remimazolam is a new reversible γ-aminobutyric acid type A agonist benzodiazepine that displays a fast onset of action, short recovery time with a safe cardiopulmonary profile and favorable pharmacokinetics in comparison with other intravenous sedatives.
Miguel T, Teixeira, Abhinav, Goyal
+5 more sources
Remimazolam is a new reversible γ-aminobutyric acid type A agonist benzodiazepine that displays a fast onset of action, short recovery time with a safe cardiopulmonary profile and favorable pharmacokinetics in comparison with other intravenous sedatives.
Miguel T, Teixeira, Abhinav, Goyal
+5 more sources
Remimazolam anaphylaxis during anesthesia induction
Journal of Anesthesia, 2021Anaphylactic shock is a potentially lethal complication during anesthesia and requires appropriate management to save the patient's life. We report a 32-year-old man who developed anaphylaxis during induction of general anesthesia with remimazolam for hand surgery. He received general anesthesia with midazolam 4 weeks before.
Kota Tsurumi +5 more
openaire +2 more sources
Drugs, 2020
Remimazolam (Anerem® in Japan; ByFavo™ in the USA; Aptimyda™ in the EU) is an ultra-short-acting intravenous (IV) benzodiazepine sedative/anesthetic being developed by PAION AG in conjunction with a number of commercial partners for use in anesthesia and procedural sedation.
openaire +2 more sources
Remimazolam (Anerem® in Japan; ByFavo™ in the USA; Aptimyda™ in the EU) is an ultra-short-acting intravenous (IV) benzodiazepine sedative/anesthetic being developed by PAION AG in conjunction with a number of commercial partners for use in anesthesia and procedural sedation.
openaire +2 more sources
Remimazolam: A Review in Procedural Sedation
Drugs, 2021Remimazolam (Byfavo™) is a benzodiazepine sedative that is indicated for the induction and maintenance of procedural sedation in adults. Remimazolam was efficacious in three phase III trials in patients requiring endoscopies. Significantly higher procedure success rates (composite of the completion of the procedure, top-up doses of study drug within ...
Arnold Lee, Matt Shirley
openaire +2 more sources
Current Opinion in Anaesthesiology
Purpose of review Remimazolam represents a novel intravenous anesthetic agent whose use began in 2020. As a new ultrashort-acting benzodiazepine, it has unique pharmacokinetic properties, such as remifentanil, designed to be active and easily transformed into inactive metabolites by tissue esterases.
Milena, Stojanovic, Radmilo, Jankovic
openaire +2 more sources
Purpose of review Remimazolam represents a novel intravenous anesthetic agent whose use began in 2020. As a new ultrashort-acting benzodiazepine, it has unique pharmacokinetic properties, such as remifentanil, designed to be active and easily transformed into inactive metabolites by tissue esterases.
Milena, Stojanovic, Radmilo, Jankovic
openaire +2 more sources
Remimazolam in neuroanesthesia
Current Opinion in AnaesthesiologyPurpose of review Remimazolam is a novel ultrashort-acting benzodiazepine that has recently gained attention for its potential benefits in neuroanesthesia. This review aims to critically assess the latest evidence regarding its hemodynamic properties, neurophysiological monitoring compatibility, and recovery profile while ...
Abramovich, Igor +2 more
openaire +1 more source